14 Mar Boston Biomedical Associates Announces the Creation of Boston Biomedical Associates Limited Tel Aviv and Names Tami Abudi and Adi Richter Co-CEO of Israeli Office
Marlborough, MA – Boston Biomedical Associates (BBA), a clinical research and consulting company based in Marlborough, MA, has announced the opening of an affiliate office, Boston Biomedical Associates Limited (BBA Ltd.) in Tel Aviv, Israel. Ms. Tami Abudi and Ms. Adi Richter have been named Co-Chief Executive Officers of Boston Biomedical Associates Limited. Ms. Abudi also serves as the Director of Clinical Development and Ms. Adi Richter as the Director of Legal Affairs.
“Opening an affiliate office in Israel will enable us to serve our Israeli clients more efficiently as the biotech and medical technology industries in that country continue to flourish,” noted Boston Biomedical Associates President and Chief Executive Officer Lauren Baker, PhD. “Boston Biomedical Associates continues to support our worldwide clients to conduct medical research internationally. The creation of our office in Tel Aviv extends our current services to our clients conducting research in Israel and other regions of the world. We are especially pleased to have Ms. Tami Abudi and Ms. Adi Richter join BBA. Tami’s expertise in medical product regulation and clinical development and Adi’s expertise as a member of the NY and Israel Bar Association, will be a great asset to all of our clients. We look forward to their leadership of the BBA Limited team,” Baker added.
In her new role at Boston Biomedical Associates, Ms. Abudi will lead the firm’s current efforts to support clients as they pursue market approval for products in Israel, Europe and the United States. Ms. Abudi will help to establish a robust team of clinical, regulatory and technology development experts who will support medical device, biotech and pharmaceutical companies developing new technologies and therapies.
Ms. Abudi has worked in clinical development for over 22 years as a senior member of medical device company leadership and a clinical and regulatory affairs consultant. Her experiences include clinical program development, quality systems development, strategic regulatory affairs consultation, regulatory submission development and interaction with regulatory agencies, in Israel, Europe and the United States.
“Boston Biomedical Associates is highly regarded in the United States and Israel for the comprehensive experience and services we offer clients who are working with various regulatory authorities to obtain approval for new and modified therapies,” Abudi said. “I am honored to be joining such a highly respected and successful team whom I have been collaborating with throughout my career. I have been working with the team from BBA for more than 20 years and now look forward to facilitating the expansion of our network of biomedical experts to expedite the global approval process for clients across the globe. The comprehensive US and Israeli team enables BBA to partner with our clients within a constantly changing regulatory environment,” she remarked.
Ms. Richter has worked as an attorney specializing in legal matters associated with corporate and commercial issues, with a particular focus on hi-tech and bio-tech companies for nearly 20 years. Her extensive experience includes intellectual property law, clinical trial agreements with various research institutions, including hospitals in the US, Europe and Canada.
“I look forward to assisting BBA’s clients with their legal matters related to the clinical, regulatory and marketing efforts,” Richter said. I believe my unique legal point of view together with the extensive expertise in the clinical field will definitely add great value to our clients,” she added.
Boston Biomedical Associates BBA serves as a strategic partner with clients involved in a variety of medical technologies and working with them throughout the entire medical product life cycle to facilitate bringing new products to market. BBA is also a leading Clinical Research Organization known for its comprehensive approach to facilitating the clinical trial operations process.